Efavirenz

證據等級: L5

預測適應症: 3 個

Efavirenz: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) originally developed for HIV-1 infection (based on general pharmacological knowledge; no verified BfArM label is present in this Evidence Pack). The TxGNN model predicts it may be effective for Simian Immunodeficiency Virus (SIV) Infection, but this signal is supported by only 1 clinical trial (unrelated drug, withdrawn) and 14 publications, all preclinical macaque-model studies — evidence is weak and largely does not describe a human clinical indication.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack — no BfArM authorization on file (0 licenses); efavirenz is generally known as an HIV-1 NNRTI, but this is not confirmed by regulatory data here
Predicted New Indication	Simian Immunodeficiency Virus Infection
TxGNN Prediction Score	99.80%
Evidence Level	L3
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as Data Gap DG002, High severity). Based on general pharmacological knowledge, efavirenz is an NNRTI that blocks HIV-1 reverse transcriptase; its efficacy in HIV-1 infection is well established in the literature, though this could not be verified against structured DrugBank data in this pack.

The predicted "new indication" — SIV infection — is not a naturally occurring human disease. It refers to a laboratory model: researchers have engineered a chimeric virus (RT-SHIV) by replacing the SIV reverse transcriptase gene with the HIV-1 reverse transcriptase gene, making it susceptible to NNRTIs like efavirenz in rhesus macaques. This allows efavirenz to suppress viral load in RT-SHIV-infected macaques (e.g., PMID 15919889, 19889213), which is almost certainly the source of the TxGNN association. Natural, non-engineered SIV is intrinsically resistant to efavirenz because wild-type SIV reverse transcriptase differs structurally from HIV-1 RT.

This means the mechanistic link is real but narrow: it applies only to an engineered laboratory tool used to study HIV pharmacokinetics and drug resistance in nonhuman primates, not to a genuine new human (or animal) therapeutic indication. Rank 2 (feline AIDS) has a similar limitation — FIV reverse transcriptase differs substantially from HIV-1 RT, and human NNRTIs including efavirenz show weak activity against wild-type FIV. Rank 3 (a rare pediatric neurodevelopmental disorder) has no mechanistic rationale and no supporting evidence at all, while efavirenz carries known CNS-related risks (dizziness, abnormal dreams, suicidal ideation) that would raise concern in this population.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00863668	NA	Withdrawn	0	Studied HIV viral decay kinetics with raltegravir (an integrase inhibitor), not efavirenz; comparison referenced SIV-infected macaque decay kinetics as background only. Trial was withdrawn (enrollment 0) and is graded C (low relevance) — drug and study population do not match this candidate.

No trials directly evaluating efavirenz in SIV infection were identified.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15328115	2004	Cohort (preclinical)	Antimicrob Agents Chemother	First demonstration that efavirenz suppresses RT-SHIV (chimeric SIV carrying HIV-1 RT) replication in rhesus macaques
15919889	2005	Cohort (preclinical)	J Virol	Efavirenz + lamivudine + tenofovir combination suppressed RT-SHIV viral load in macaques, modeling human HAART
19889213	2009	Cohort (preclinical)	Retrovirology	Short-course efavirenz monotherapy followed by combination ART in RT-SHIV-infected macaques; tracked viral subpopulation dynamics
21084490	2011	Review/Cohort	J Virol	Efavirenz monotherapy in pigtail macaques prior to combination ART; genetic diversity of RT-SHIV persisted despite treatment
24777106	2014	Cohort (preclinical)	Antimicrob Agents Chemother	Enhanced 4–5 drug ART regimens (context includes efavirenz-based models) improved RT-SHIV decay kinetics in macaques
20668516	2010	Preclinical	PLoS One	Characterized viral decay kinetics in HAART-treated RT-SHIV macaque model of AIDS
26559632	2015	Preclinical	Retrovirology	Plasma/tissue viral population analysis in RT-SHIV macaques on ART suggests no residual tissue replication
20032180	2010	Preclinical	J Virol	Identified viral sanctuaries persisting during HAART in the RT-SHIV nonhuman primate AIDS model
22933296	2012	In vitro	J Virol	Ultrasensitive PCR detected rare pre-existing drug-resistant RT-SHIV variants in macaques prior to ART
35856680	2022	In vitro/Imaging	Antimicrob Agents Chemother	Mass spectrometry imaging mapped antiretroviral drug distribution and residual RT-SHIV RNA in macaque spleen tissue

Note: All identified literature describes the engineered RT-SHIV macaque research model used to study human HIV-1 pharmacology and resistance — none describes treatment of naturally occurring SIV infection as a disease target.

Germany Market Information

Efavirenz currently holds no marketing authorization on record in this Evidence Pack (0 licenses; market status: not marketed). BfArM label content (warnings, contraindications, approved indications) could not be retrieved and is tracked as Data Gap DG001 (Blocking).

Safety Considerations

Please refer to the package insert for safety information. Structured warning, contraindication, and drug-interaction data (TFDA/BfArM label) are not yet available for efavirenz in this Evidence Pack — retrieval of the official label PDF is tracked as Data Gap DG001 (Blocking), which currently prevents a full S1 safety review.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication (SIV infection) reflects an engineered laboratory research model (RT-SHIV in macaques) rather than a genuine treatable disease target; the only associated clinical trial is unrelated and withdrawn; and both regulatory safety data (DG001, Blocking) and mechanism-of-action data (DG002, High) are missing, preventing progression past S0.

To proceed, the following is needed:

Retrieve and parse the official TFDA/BfArM label PDF for warnings and contraindications (DG001)
Query DrugBank (or equivalent) to confirm and document efavirenz's mechanism of action (DG002)
Clarify with the TxGNN/evidence pipeline whether "simian immunodeficiency virus infection" should be excluded as a non-human, model-only node, since it does not represent an actionable repurposing target
Re-screen ranks 2 (feline AIDS — veterinary, not human) and 3 (ultra-rare neurodevelopmental disorder — no evidence, potential CNS safety conflict) before considering any further evaluation of this candidate set
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.